The 82nd Annual Meeting of
The Japanese Pharmacological Society
March 16-18, 2009
Yokohama, Japan
Chairman: Shigeru Motomura
Abstracts
Secretariat: Ken-Ichi Furukawa
Hirosaki University Graduate School of Medicine
Contents
Plenary Lecture
PL
Two Mouse Tales
Oliver Smithies.......... 2P
Special Lectures
SL1
α-Blockers and male voiding dysfunction: Lessons for the interaction
between academia and industry
Martin C. Michel .......... 4P
SL2
The drug discovery and management skills I learnt at the Japanese
Pharmacological Society (JPS)
Toichi Takenaka .......... 4P
SL3
Structure-guided molecular targeting approach in the development of AIDS therapeutics
Hiroaki Mitsuya .......... 4P
SL4
Mysterious blank of twenty seven hours
-The Eighth Division Commander Tatsumi and Major Yamaguchi's death-
Akitomo Matsuki .......... 4P
SL5
Development of new lymphology combined with cardiovascular medicine,
oncology, and innate immunology
Toshio Ohhashi .......... 5P
SL6
Aβ oligomers as the diagnostic and therapeutic target for Alzheimer disease
Colin L. Masters .......... 5P
Ebashi Setsuro Award Lecture
EAL
Induction of pluripotency by defined factors
Shinya Yamanaka ............ 8P
Award Lectures
AL1
Possible involvement of HRD1 (ubiquitin E3 ligase) in neurodegenerative diseases
Masayuki Kaneko ............ 10P
AL2
Discovery and neuroprotective mechanisms of 'serofendic acid' derived from
fetal calf serum
Toshiaki Kume ............ 10P
AL3
Analysis of the mechanism underlying formation of the endocochlear
potential in the inner ear
Hiroshi Hibino ............ 10P
4th Japan-China Joint Meeting of Basic and Clinical
Pharmacology (JCM)
Supported by The IUPHAR Committee of the Science Council of Japan
JCM1-PL1
Ginsenoside-Rd, a new voltage-independent Ca2+ entry
blocker, reverses basilar
hypertrophic remodeling in stroke-prone renovascular hypertensive rats
Guan Yong-Yuan ............ 12P
JCM1-PL2
Intracellular Ca2+ release mechanisms and central nervous system functions
Masamitsu Iino ............ 12P
JCM1-1
Selective immunosuppression: A new approach to the treatment of immune diseases
Xu Qiang ............ 12P
JCM1-2
Nobiletin from citrus peels improves the memory impairment in Alzheimer's
disease model animals - its application to functional foods and medicines
Yasushi Ohizumi ............ 12P
JCM1-3
Cardioprotection of vagus against ischemic injury
Zang Wei-Jin ............ 13P
JCM1-4
Molecular PET imaging in Alzheimer disease: From basic development to clinical
application
Kazuhiko Yanai ............. 13P
JCM2-PL1
Usefulness of in vivo analysis of drug-receptor binding characteristics
in drug discovery
Shizuo Yamada ............. 13P
JCM2-PL2
Current status of clinical trials on anticancer drugs in China
Shi Yuankai ............ 13P
JCM2-1
Pharmacogenomics: Potential role in the clinical trails
Yi-min Cui ............ 14P
JCM2-2
Current management of lung cancer: Targeted therapy
Takeshi Isobe ............. 14P
JCM2-3
Herb-drug interaction: Application in the renal transplant recipients
Huang Min ............ 14P
JCM2-4 Efficacy and safety of amiodarone therapy in Japanese patients
Takeshi Shiga ............ 14P
Symposia
S1A-1
Pharmacological and non-pharmacological approaches to atrial fibrillation:
Current status and new perspective
Ken Okumura and Haruaki Nakaya ............ 16P
S1B-2
New approaches to blockade of the renin-angiotensin-aldosterone system
Shokei Mitsuyama and Akira Nishiyama ............ 17P
S1C-3
New therapeutic approaches to heart failure, targeting cardiac lipid metabolism
Takahiro Iwamoto and Satomi Adachi-Akahane ............ 18P
S1D-4
Reactive oxygen species implicated in the pathophysiology of various diseases
- An update for pharmacological intervention -
Tetsuo Nakata and Chihiro Yabe ............ 19P
S1E-5
Nonsense-mediated mRNA decay (NMD) in genetic disorders:
Pathophysiology and drug development
Yayoi Shikama and Shigeo Ohno ............ 20P
S1A-6
Factors that affect sensitivity and resistance to chemotherapeutic agents and
molecular targeted therapy - Pharmacogenomics in cancer chemotherapy -
Supported by The Functional Medical Science Committee
Shin-ichi Akiyama and Yasutsuna Sasaki ............ 22P
S1B-7
Pathophysiology and therapeutic drug strategies in transgenic mouse model:
A view point of cardiovascular and psychological diseases
Nobuyuki Yanagihara and Haruhiro Higashidav ............ 23P
S1C-8
Apoptosis-related molecules as a therapeutic target for different diseases
Yuichi Hattori and Kazuhiro Takuma ............ 24P
S3L-9
Development of drug therapy for the neuronal dysfunction based upon the
pathophysiology of life style-related disease
Junzo Kamei and Hiromu Kawasaki ............ 25P
S1E-10
Roles of oral bacteria on cardiovascular diseases - Molecular mechanisms to
clinical cases
Kazuo Umemura and Koichiro Wada ............ 26P
S2A-11
Activation of drug discovery research and industry-academia-government cooperation
Toichi Takenaka and Hideaki Hara ............ 27P
S2B-12
Development of etiology/pathophysiology-based animal models for psychiatric
disorders and the application for drug development
Mitsuhiro Yoshioka and Kiyofumi Yamada ............ 29P
S2C-13
Non-degenerative neuronal disaease; from molecular basis to bed side
Naoaki Saito and Kozo Kaibuchi ............ 30P
S2D-14
Advanced research of dopamine signaling to develop drugs for mental disorders
Kohji Fukunaga and Akinori Nishi ............ 31P
S2E-15
Development of novel therapeutic strategies for HIV/AIDS
Takeya Sato and Masanori Baba ............ 32P
S2B-16
New horizon of transporter research: Technologies to approach drug targets
and related diseases
Yoshikatsu Kanai and Hiroshi Suzuki ............ 33P
S2C-17
The forefront for novel therapeutic agents based on pathophysiology of lower
urinary tract dysfunction
Masayuki Takeda and Shizuo Yamada ............ 35P
S2D-18
Recent advances in G-protein coupled receptors: Receptor dynamics and intracellular
signaling
Soichi Miwa and Jun Sukegawa ............ 36P
S3A-19
Novel function of G protein-coupled receptors
Norimichi Nakahata and Hitoshi Kurose ............ 37P
S3C-20
New features and pathophysiological roles of TRP channel proteins
Motohiro Nishida and Ryuji Inoue ............ 38P
S3D-21
Pharmacogenomics of novel animal model for life style diseases
Toshio Tanaka and Gozoh Tsujimoto ............ 40P
S3E-22
Glial dysfunction and neuronal diseases
Schuichi Koizumi and Yasushi Enokido ............ 41P
S3A-23
Novel etiological and therapeutically strategies for neurodiseases
Takeshi Suzuki and Yuji Ikegaya ............ 42P
S3C-24
Regulation of membrane protein surface expression: Fundamental
mechanisms, pathological implications and beyond
Kuniaki Ishii and Masato Hirata ............ 43P
S3D-25
New therapeutic strategies for allergic diseases by rectification of
the abnormal immuno-allergic network
Kazutaka Maeyama and Hiroyuki Fukui ............ 44P
S3E-26
New frontiers in the gut nutrient sensor research
Koji Takeuchi and Hisayuki Uneyama ............ 46P
Free Communications
Oral Sessions ......... 49P
Poster Sessions .......... 123P
Author Index ............. 1
Subject Index ............. 39
Subscription/back issue orders: to Subscription Information
| |
Copyright The Japanese Pharmacological Society |
|
Copyright(C) The Japanese Pharmacological Society All Rights Reserved. |